June 2026 Nestlé Health Science expanded its food allergy nutrition portfolio through continued development of specialized nutritional solutions for individuals with food allergies and intolerances. The company focused on advancing medical nutrition products designed to support allergy management and improve dietary options for affected populations.
May 2026 DBV Technologies advanced its Viaskin™ peanut allergy immunotherapy program through continued clinical and regulatory activities. The company focused on improving non-invasive epicutaneous immunotherapy approaches using its proprietary skin patch technology to support peanut allergy treatment.
April 2026 ALK-Abelló expanded its allergy immunotherapy research and development activities with continued investments in diagnostic and treatment solutions for allergic diseases, including food-related allergies. The company focused on advancing precision allergy care through improved testing methods and immunotherapy technologies.
February 2026 Aimmune Therapeutics expanded its peanut allergy treatment initiatives following continued commercialization and development activities around PALFORZIA®, the first FDA-approved oral immunotherapy product for peanut allergy. The company focused on improving treatment accessibility and supporting healthcare providers in allergy management.